Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 6/20 | 0.39 |
| ▸ | CA5A | P35218 | 5/20 | 0.39 |
| ▸ | CA4 | P22748 | 4/20 | 0.39 |
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | CA9 | Q16790 | 4/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA7 | P43166 | 3/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triphenylphosphine Oxide SCHEMBL1597562 | 1.00 | LMNA (0.39) | LMNACA2CA5ACA4CA1 | |
| Triphenylphosphine Oxide SCHEMBL3949 | 0.75 | CA2 (0.58) | LMNACA2CA5ACA4KMT2A | |
| Triphenylphosphine Oxide SCHEMBL513223 | 0.75 | CA2 (0.58) | LMNACA2CA5ACA4KMT2A | |
| Triphenylphosphine Oxide SCHEMBL8328973 | 0.73 | CA2 (0.52) | LMNACA2CA5ACA4KMT2A | |
| Triphenylphosphine Oxide SCHEMBL7991003 | 0.72 | CA2 (0.55) | LMNACA2CA5ACA4KMT2A | |
| SCHEMBL5439069 | 0.72 | LMNA (0.60) | LMNACA2CA5ACA4KMT2A | |
| Triphenylphosphine Oxide SCHEMBL7551485 | 0.72 | CA2 (0.55) | LMNACA2CA5ACA4KMT2A | |
| Triphenylphosphine Oxide SCHEMBL9425396 | 0.72 | CA2 (0.55) | LMNACA2CA5ACA4KMT2A | |
| SCHEMBL132983 | 0.72 | LMNA (0.60) | LMNACA2CA5ACA4KMT2A | |
| Triphenylphosphine Oxide SCHEMBL8431251 | 0.72 | CA2 (0.63) | LMNACA2CA5ACA4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1642880-B1 | HSP90 FAMILY PROTEIN INHIBITORS | KYOWA HAKKO KIRIN CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| EP-2487175-A1 | PHARMACEUTICAL PRODUCT CONTAINING AROMATIC HETEROCYCLIC COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20120196854-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AROMATIC HETEROCYCLIC COMPOUND | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-08-02 | — | — | US | disclosed |
| US-7781485-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-7767693-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-08-03 | — | — | US | disclosed |
| US-7605272-B2 | IGF-1R inhibitor | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-10-20 | — | — | US | disclosed |
| US-20090247522-A1 | Hsp90 FAMILY PROTEIN INHIBITORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-10-01 | — | — | US | disclosed |
| US-7538224-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-26 | — | — | US | disclosed |
| US-7538241-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20090054508-A1 | IGF-1R INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| US-20070155813-A1 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-07-05 | — | — | US | disclosed |
| US-20070117856-A1 | Indazole derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-24 | — | — | US | disclosed |
| US-20070032532-A1 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20070004674-A1 | Remedy for diseases associated with immunoglobulin gene translocation | KYOWA HAKKO KOGYO CO. LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
| EP-1704856-A1 | HSP90 FAMILY PROTEIN INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-27 | — | — | EP | disclosed |
| EP-1666064-A1 | REMEDY FOR DISEASES ASSOCIATED WITH IMMUNOGLOBULIN GENE TRANSLOCATION | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-06-07 | — | — | EP | disclosed |
| EP-1652842-A1 | INDAZOLE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-05-03 | — | — | EP | disclosed |
| EP-1642880-A1 | HSP90 FAMILY PROTEIN INHIBITORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-04-05 | — | — | EP | disclosed |
| US-20060058366-A1 | Jnk inhibitor | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-03-16 | — | — | US | disclosed |
| EP-1582211-A1 | JNK INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032532-A1 | Hsp90 family protein inhibitors | HSP90AB1, HSP90B1, HSP90AB2P | LMNA 4283/4885CA2 3354/4885CA5A 4386/4885 |
| US-20090247522-A1 | Hsp90 FAMILY PROTEIN INHIBITORS | HSP90AB1, HSP90B1, HSP90AB2P | LMNA 4283/4885CA2 3354/4885CA5A 4386/4885 |
| US-20070117856-A1 | Indazole derivatives | IGF1R, NR0B2, ADRA2B | LMNA 1833/4885CA2 2842/4885CA5A 3041/4885 |
| US-20070004674-A1 | Remedy for diseases associated with immunoglobulin gene translocation | HSP90B1, HSP90AA1, HSP90AB1 | LMNA 3051/4885CA2 3927/4885CA5A 3919/4885 |
| US-20070155813-A1 | Hsp90 family protein inhibitors | HSP90AB1, HEATR1, HSP90AB2P | LMNA 4706/4885CA2 3499/4885CA5A 4524/4885 |
| US-20090054508-A1 | IGF-1R INHIBITOR | IGF1R, IGFBP5, IGFBP1 | LMNA 4397/4885CA2 3257/4885CA5A 1991/4885 |
| US-20120196854-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AROMATIC HETEROCYCLIC COMPOUND | CYP2C18, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2B6 | LMNA 2761/4885CA2 2053/4885CA5A 2312/4885 |
| US-20060058366-A1 | Jnk inhibitor | MAPK3, MAPK4, MAPKAPK3 | LMNA 4618/4885CA2 3920/4885CA5A 4439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.